We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+12.84%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$558M
AUM Growth
+$54.7M
Cap. Flow
+$23.7M
Cap. Flow %
4.24%
Top 10 Hldgs %
57.55%
Holding
51
New
14
Increased
7
Reduced
11
Closed
13

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$33.5M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$17M
3
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$15M
4
PCRX icon
Pacira BioSciences
PCRX
+$13.9M
5
RNAC icon
Cartesian Therapeutics
RNAC
+$13.8M

Top Sells

Rank Stock Value
1
TXMD icon
TherapeuticsMD
TXMD
+$24.9M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$15.2M
3
RXDX
Ignyta, Inc.
RXDX
+$10.7M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$10.4M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$7.34M

Sector Composition

Rank Sector Weight
1 Healthcare 79.15%
2 Technology 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASC
51
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-377,900
Closed -$1.56M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Great Point Partners held 51 positions worth $558M, up 11% from $504M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners deployed $23.7M of net new capital in Q2 2017, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Arena Pharmaceuticals Inc: 2,439,930 shares worth $41.2M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ignyta, Inc., an estimated $10.7M trimmed.

  • Great Point Partners's largest Q2 2017 buy was Arena Pharmaceuticals Inc: 2,439,930 shares worth $41.2M.
  • Great Point Partners added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $17M increase.
  • Great Point Partners's biggest Q2 2017 reduction was Ignyta, Inc., cutting an estimated $10.7M.
  • Great Point Partners fully exited TherapeuticsMD in Q2 2017, selling an estimated $24.9M.
  • Great Point Partners's ten largest holdings make up 58% of its $558M portfolio in Q2 2017.
  • Great Point Partners opened 14 new positions and closed 13 in Q2 2017.
  • Great Point Partners's portfolio value rose 11% quarter-over-quarter to $558M.

Based on Great Point Partners's 13F filing for Q2 2017, filed 14 Aug 2017.